Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
AssigneeOregon Health Sciences University
InventorsGregory G. Burrows, Arthur A. Vandenbark
Life of this patent
Estimating the term…
Abstract
Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells.
Claims18
A purified MHC Class II polypeptide comprising covalently linked first and second domains, wherein:
- the first domain is a mammalian MHC class II β1 domain and the second domain is a mammalian MHC class II α1 domain
- and wherein the amino terminus of the second domain is covalently linked to the carboxy terminus of the first domain and wherein the MHC class II molecule does not include an α2 or a β2 domain.
A recombinant polypeptide comprising α1 and β1 domains of a mammalian MHC class II molecule wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, and wherein the MHC class II molecule does not include either an α2 domain or a β2 domain.
A recombinant polypeptide comprising only two domains of an MHC class II peptide, wherein the two domains are an α1 domain and a β1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain.
Dependencies are inferred from the claim text.